ArticleOxford medical case reports2025
Gastrointestinal herpes zoster in a patient on infliximab: a case report.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Varicella-zoster virus (VZV) reactivation in immunocompromised patients may present atypically, including with severe gastrointestinal involvement. We present a case of a 36-year-old male with ileocolic Crohn's disease, who, following Infliximab (IFX) therapy, developed severe gastrointestinal symptoms. Subsequent investigations confirmed a disseminated VZV infection with esophagogastric and duodenal involvement. Our case highlights the crucial need for heightened clinical awareness regarding unusual VZV presentations in immunocompromised patients, especially those receiving TNF- α inhibitors such as Infliximab, known to increase the risk of VZV reactivation. Given the potentially high mortality rate (approximately 40%) associated with gastrointestinal VZV involvement, prompt and aggressive antiviral treatment is imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.